Pharmabiz14h
Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis
Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...
MyChesCo on MSN4d
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a revised operating plan as it evaluates a range of ...
Targeted Oncology5d
Disease Site and Access Factor into Selection of GVHD Therapy
During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...
Carisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $1 from $12 and keeps a Buy rating on the shares after the ...
Fierce Biotech6d
Carisma winds down operations, lays off 95% of remaining staff
After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...